FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Harris Matthew Scott					Altir	2. Issuer Name and Ticker or Trading Symbol Altimmune, Inc. [ALT]								5. Relationship of Reporting Person(s) to Issue (Check all applicable) Director 10% Owner						
(Last)	,	,	Middle)			3. Date of Earliest Transaction (Month/Day/Year) 09/09/2019								X	below)	,		Other (s	pecify	
C/O ALTIMMUNE, INC.														Chief Medical Officer						
910 CLOPPER ROAD, SUITE 201S					4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)														X Form filed by One Reporting Person					n	
GAITHERSBURG MD 20878													Form filed by More than One Reporting Person							
(City)	(Si	tate) (Zip)																	
		Tab	le I - N	on-Deri	ative S	Sec	urities	Acc	quired, D	isp	osed o	f, or Bei	neficia	lly	Owned					
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day)						Execution Date,			Transaction Disposed Of (I Code (Instr. and 5)				s Acquired (A) or of (D) (Instr. 3, 4			nt of es ally	Form (D) o	: Direct r ect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code				v	Amount	nt (A) or (D))	Followir Reported Transact (Instr. 3	ed ction(s)		. 4)	msu. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date curity or Exercise (Month/Day/Year) if any			on Date,	Date, Transact				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			. Price f lerivative lecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership	
		Code			Date Exp Exercisable Date		xpiration ate	Amo or Num of Title Shar												
Stock Options (option to buy)	\$2.13	09/09/2019			A		107,000		(1)	0	9/09/2029	Common Stock, par value \$0.0001	107,00	0	\$0.00	107,00	00	D		

Explanation of Responses:

1. Twenty-five percent of the shares underlying the option become vested and exercisable on September 9, 2020 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following September 9, 2020, subject to the reporting person's continued service through the applicable vesting date.

Remarks:

/s/ Matthew Scott Harris 09/11/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{*} If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).